Boston Scientific BSX shares are continuing higher on Wednesday following a report that the company is putting its snake venom unit up for sale.
Boston Scientific produces less-invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract tests, interventional oncology, and treatment of incontinence.
Boston Scientific shares were trading up 3.51% to $36.44 at time of publication on Wednesday. The stock has a 52-week high of $46.62 and a 52-week low of $24.10.
Related Link:
Varian Will Acquire Embolic Bead Asset From Boston Scientific
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
